US2011045059A1PendingUtilityA1

Vaccine against varicella zoster virus

47
Assignee: GLAXOSMITHKLINE BIOLOG SAPriority: Mar 3, 2005Filed: May 20, 2010Published: Feb 24, 2011
Est. expiryMar 3, 2025(expired)· nominal 20-yr term from priority
Inventors:Emmanuel Jules HanonJean Stephenne
A61P 37/04A61P 25/00A61P 31/00A61P 31/22A61P 29/00A61P 31/18A61P 25/04A61K 2039/55555A61K 2039/55577A61K 39/12C07K 14/005A61K 2039/5252A61K 39/25C12N 2710/16722A61K 2039/5254C12N 2710/16734A61K 2039/55572A61K 39/00A61K 39/39
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed

Claims

exact text as granted — not AI-modified
1 . A method of preventing herpes zoster reactivation in an individual, said method comprising sequential delivery of:
 a live attenuated or whole inactivated varicella-zoster virus (VZV); and   an immunogenic composition comprising VZV gE, 3D-MPL and QS21.   
     
     
         2 . The method of  claim 1 , wherein 3D-MPL is provided in liposomes. 
     
     
         3 . The method of  claim 2 , wherein the liposomes comprise cholesterol. 
     
     
         4 . The method of  claim 1 , wherein two or more immunizations are employed. 
     
     
         5 . The method of  claim 4 , wherein the immunogenic composition is delivered first, followed by delivery of the live attenuated or whole inactivated VZV. 
     
     
         6 . The method of  claim 1 , wherein the live attenuated or whole inactivated VZV is delivered first, followed by delivery of the immunogenic composition. 
     
     
         7 . The method of  claim 1 , wherein the live attenuated or whole inactivated VZV and the immunogenic composition are administered in a two dose regime comprising between 1-6 months between individual immunizations. 
     
     
         8 . The method of  claim 7 , wherein the immunogenic composition is administered between 1-6 months following the delivery of the live attenuated or whole inactivated VZV. 
     
     
         9 . The method of  claim 7 , wherein the live attenuated or whole inactivated VZV is delivered between 1-6 months following the delivery of the immunogenic composition. 
     
     
         10 . The method of  claim 1 , wherein the VZV is a live attenuated OKA strain. 
     
     
         11 . The method according to  claim 1 , wherein the gE is a truncate. 
     
     
         12 . The method according to  claim 11 , wherein the gE is a C-terminal truncate. 
     
     
         13 . The method according to  claim 12 , wherein the gE has the amino acid sequence of SEQ ID NO: 1. 
     
     
         14 . The method of  claim 1 , wherein between 25-100 μg of VZV gE are delivered. 
     
     
         15 . The method of  claim 14 , wherein between 40-100 μg of VZV gE are delivered. 
     
     
         16 . The method of  claim 1 , further comprising repeating the delivery of the live attenuated or whole inactivated VZV. 
     
     
         17 . The method of  claim 16 , comprising repeating the delivery of the live attenuated or whole inactivated VZV two or more times. 
     
     
         18 . The method according to  claim 1 , wherein the sequential delivery is administered to an individual of at least 50 years of age. 
     
     
         19 . The method according to  claim 1 , wherein the sequential delivery is administered to an immunocompromised individual. 
     
     
         20 . A method of ameliorating the severity of herpes zoster reactivation and/or post herpetic neuralgia in an individual, said method comprising sequential delivery of
 a live attenuated or whole inactivated varicella-zoster virus (VZV); and   an immunogenic composition comprising VZV gE, 3D-MPL and QS21.   
     
     
         21 . The method of  claim 20 , wherein 3D-MPL is provided in liposomes. 
     
     
         22 . The method of  claim 21 , wherein the liposomes comprise cholesterol. 
     
     
         23 . The method of  claim 20 , wherein two or more immunizations are employed. 
     
     
         24 . The method of  claim 23 , wherein the immunogenic composition is delivered first, followed by delivery of the live attenuated or whole inactivated VZV. 
     
     
         25 . The method of  claim 20 , wherein the live attenuated or whole inactivated VZV is delivered first, followed by delivery of the immunogenic composition. 
     
     
         26 . The method of  claim 20 , wherein the live attenuated or whole inactivated VZV and the immunogenic composition are administered in a two dose regime comprising between 1-6 months between doses. 
     
     
         27 . The method of  claim 26 , wherein the immunogenic composition is administered between 1-6 months following the delivery of the live attenuated or whole inactivated VZV. 
     
     
         28 . The method of  claim 26 , wherein the live attenuated or whole inactivated VZV is delivered between 1-6 months following the delivery of the immunogenic composition. 
     
     
         29 . The method of  claim 20 , wherein the VZV is a live attenuated OKA strain. 
     
     
         30 . The method according to  claim 20 , wherein the gE is a truncate. 
     
     
         31 . The method according to  claim 30 , wherein the gE is a C-terminal truncate. 
     
     
         32 . The method according to  claim 31 , wherein the gE has the amino acid sequence of SEQ ID NO: 1. 
     
     
         33 . The method of  claim 20 , wherein between 25-100 μg of VZV gE are delivered. 
     
     
         34 . The method of  claim 33 , wherein between 40-100 μg of VZV gE are delivered. 
     
     
         35 . The method of  claim 20 , further comprising repeating the delivery of the live attenuated or whole inactivated VZV. 
     
     
         36 . The method of  claim 35 , comprising repeating the delivery of the live attenuated or whole inactivated VZV two or more times. 
     
     
         37 . The method according to  claim 20 , wherein the sequential delivery is administered to an individual of at least 50 years of age. 
     
     
         38 . The method according to  claim 1 , wherein the sequential delivery is administered to an immunocompromised individual. 
     
     
         39 . A method of preventing herpes zoster reactivation in an individual, said method comprising concomitant delivery of
 a live attenuated or whole inactivated varicella-zoster virus (VZV); and   an immunogenic composition comprising VZV gE, 3D-MPL and QS21.   
     
     
         40 . A method of ameliorating the severity of herpes zoster and/or post herpetic neuralgia in an individual, said method comprising a concomitant delivery of
 a live attenuated or whole inactivated varicella-zoster virus (VZV); and   an immunogenic composition comprising VZV gE, 3D-MPL and QS21.

Join the waitlist — get patent alerts

Track US2011045059A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.